Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh. The inspection, originally conducted as a GMP and Pre-Approval Inspection (PAI), has been officially closed under 21 CFR 20.64(d)(3). The USFDA classified the outcome as 'Voluntary Action Indicated (VAI)', which is the most favorable of the three possible classifications. This follows the company's earlier intimation dated December 12, 2025, about the inspection. The VAI classification means the facility is considered to be in an acceptable state of compliance with no mandatory corrective action required.
This is a positive development for Dr. Reddy's as the VAI classification removes regulatory overhang on the Srikakulam facility and supports smoother product approvals from this site going forward. It should be viewed favorably by investors monitoring the company's USFDA compliance profile.